(Total Views: 484)
Posted On: 01/29/2021 9:38:12 AM
Post# of 155026
Paulson & Fife payments/warrants (correct me if I'm wrong!) -
So Paulson is making good on some old warrants, netting the company approx $2.75mm (inclusive of expenses), and I believe this goes straight to their "paid in capital" balance sheet line item so it gets CYDY closer to Nasdaq compliance, but still more to go.
Not in this 8k, but looks like Fife will be getting around 1.5mm shares to satisfy the Jan $7.5mm payment to bring the loan payable amount down to $13.5mm from $21mm.
Fife will then have 600k left on the previous shelf, and I'd imagine CYDY will register another ~750k in February (to make 1.35mm total, which, if converted at the $10 convert price specified in the Fife deal, pays off the remaining $13.5mm).
So total dilution b/w Paulson warrants + Fife, assuming we go above $10 next month, is 3.56mm (paulson) + 1.5mm (fife in Jan) + 1.35mm in Feb (fife) = 6.41mm shares divided by 590mm shares outstanding = ~1.1% of dilution
So the stock price should in theory go down 1.1% based on dilution. Not bad imo to help cleanup the balance sheet and get us closer to Nasdaq compliance.
All the above irrelevant over the long term as the potential LL revenue's will enable the company to buyback stock to anti-dilute the shareholders... unless of course they save some cash to start buying up smaller promising biotech's or drug distribution companies in their efforts to move up into big pharma land... both options sound great to me!
So Paulson is making good on some old warrants, netting the company approx $2.75mm (inclusive of expenses), and I believe this goes straight to their "paid in capital" balance sheet line item so it gets CYDY closer to Nasdaq compliance, but still more to go.
Not in this 8k, but looks like Fife will be getting around 1.5mm shares to satisfy the Jan $7.5mm payment to bring the loan payable amount down to $13.5mm from $21mm.
Fife will then have 600k left on the previous shelf, and I'd imagine CYDY will register another ~750k in February (to make 1.35mm total, which, if converted at the $10 convert price specified in the Fife deal, pays off the remaining $13.5mm).
So total dilution b/w Paulson warrants + Fife, assuming we go above $10 next month, is 3.56mm (paulson) + 1.5mm (fife in Jan) + 1.35mm in Feb (fife) = 6.41mm shares divided by 590mm shares outstanding = ~1.1% of dilution
So the stock price should in theory go down 1.1% based on dilution. Not bad imo to help cleanup the balance sheet and get us closer to Nasdaq compliance.
All the above irrelevant over the long term as the potential LL revenue's will enable the company to buyback stock to anti-dilute the shareholders... unless of course they save some cash to start buying up smaller promising biotech's or drug distribution companies in their efforts to move up into big pharma land... both options sound great to me!
(5)
(0)
